NCT05070403View on ClinicalTrials.gov

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions

Squamous Cell Carcinoma

Interventions

DRUG

Afatinib 40 MG

Participants will receive 40 mg Afatinib, once daily.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05070403 - Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter